• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Efficacy of furosemide for treatment of liver cirrhosis: A systematic review protocol of randomized controlled trial.呋塞米治疗肝硬化的疗效:一项随机对照试验的系统评价方案
Medicine (Baltimore). 2019 Apr;98(16):e15300. doi: 10.1097/MD.0000000000015300.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Clinical Yi-guan decoction for liver cirrhosis: A protocol for systematic review and meta analysis.治疗肝硬化的临床一贯煎:系统评价与Meta分析方案
Medicine (Baltimore). 2021 Apr 2;100(13):e24530. doi: 10.1097/MD.0000000000024530.
4
Efficacy of ivabradine for heart failure: A protocol for a systematic review of randomized controlled trial.伊伐布雷定治疗心力衰竭的疗效:一项随机对照试验系统评价方案
Medicine (Baltimore). 2019 Apr;98(14):e15075. doi: 10.1097/MD.0000000000015075.
5
Effectiveness of rehabilitation training combined with acupuncture on aphasia after cerebral hemorrhage: A systematic review protocol of randomized controlled trial.康复训练联合针刺治疗脑出血后失语症的疗效:一项随机对照试验的系统评价方案
Medicine (Baltimore). 2019 Jun;98(24):e16006. doi: 10.1097/MD.0000000000016006.
6
Efficacy of sertraline for post-stroke depression: A systematic review protocol of randomized controlled trial.舍曲林治疗卒中后抑郁的疗效:一项随机对照试验的系统评价方案
Medicine (Baltimore). 2019 Apr;98(16):e15299. doi: 10.1097/MD.0000000000015299.
7
Green tea extract for treatment of cancers: A systematic review protocol.绿茶提取物治疗癌症:一项系统评价方案
Medicine (Baltimore). 2019 Apr;98(15):e15117. doi: 10.1097/MD.0000000000015117.
8
Effectiveness of extracorporeal shock-wave therapy for frozen shoulder: A protocol for a systematic review of randomized controlled trial.体外冲击波疗法治疗肩周炎的有效性:一项随机对照试验系统评价的方案
Medicine (Baltimore). 2019 Feb;98(7):e14506. doi: 10.1097/MD.0000000000014506.
9
Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.Janus 激酶抑制剂治疗白癜风的系统评价和荟萃分析方案。
Syst Rev. 2024 Apr 19;13(1):110. doi: 10.1186/s13643-024-02522-3.
10
Electrical stimulation for limb spasticity in children with traumatic brain injury: Study protocol for a systematic review of randomized controlled trial.创伤性脑损伤患儿肢体痉挛的电刺激治疗:一项随机对照试验系统评价的研究方案
Medicine (Baltimore). 2019 Feb;98(8):e14515. doi: 10.1097/MD.0000000000014515.

本文引用的文献

1
Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges.肝硬化患者的睡眠障碍:患病率、影响及管理挑战。
Nat Sci Sleep. 2018 Nov 2;10:369-375. doi: 10.2147/NSS.S186665. eCollection 2018.
2
Peritoneal Dialysis for Patients with End-Stage Renal Disease and Liver Cirrhosis.终末期肾病合并肝硬化患者的腹膜透析
Perit Dial Int. 2018 Nov-Dec;38(6):397-401. doi: 10.3747/pdi.2018.00008.
3
Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test.肝硬化患者糖尿病的诊断及临床意义:聚焦口服葡萄糖耐量试验
J Endocr Soc. 2017 May 23;1(7):886-896. doi: 10.1210/js.2017-00183. eCollection 2017 Jul 1.
4
Improving Quality of Care in Patients with Liver Cirrhosis.改善肝硬化患者的医疗质量。
Middle East J Dig Dis. 2017 Oct;9(4):189-200. doi: 10.15171/mejdd.2017.73.
5
Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis.肝硬化患者肌肉减少症的预后价值:一项系统评价和荟萃分析。
PLoS One. 2017 Oct 24;12(10):e0186990. doi: 10.1371/journal.pone.0186990. eCollection 2017.
6
High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis.高剂量口服呋塞米联合摄盐治疗肝硬化难治性腹水
Clin Invest Med. 2016 Dec 1;39(6):27502.
7
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis.直接作用抗病毒药物治疗丙型肝炎相关肝硬化
Gut Liver. 2017 May 15;11(3):335-348. doi: 10.5009/gnl15458.
8
Evidence-based clinical practice guidelines for liver cirrhosis 2015.2015 年肝硬化循证临床实践指南。
J Gastroenterol. 2016 Jul;51(7):629-50. doi: 10.1007/s00535-016-1216-y. Epub 2016 May 31.
9
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis.1980年至2010年间187个国家的肝硬化死亡率:一项系统分析。
BMC Med. 2014 Sep 18;12:145. doi: 10.1186/s12916-014-0145-y.
10
Influence of unrecorded alcohol consumption on liver cirrhosis mortality.未记录的酒精消费量对肝硬化死亡率的影响。
World J Gastroenterol. 2014 Jun 21;20(23):7217-22. doi: 10.3748/wjg.v20.i23.7217.

呋塞米治疗肝硬化的疗效:一项随机对照试验的系统评价方案

Efficacy of furosemide for treatment of liver cirrhosis: A systematic review protocol of randomized controlled trial.

作者信息

Zhu Zheng-Ri, Liu Wan-Lu, Ding Zhao-Min, Li Yue

机构信息

Second Ward of Gastroenterology Department.

Department of Nursing Care.

出版信息

Medicine (Baltimore). 2019 Apr;98(16):e15300. doi: 10.1097/MD.0000000000015300.

DOI:10.1097/MD.0000000000015300
PMID:31008980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6494370/
Abstract

BACKGROUND

Previous clinical studies have reported that furosemide can be used to treat liver cirrhosis (LC) effectively. However, no study systematically explored this issue. This systematic review aims to investigate the efficacy and safety of furosemide for treatment of LC.

METHODS

This study will be conducted through searching the following literature sources from their inception to February 28, 2019 without any language limitations: PUBMED, EMBASE, PsycINFO, Web of Science, Scopus, OpenGrey, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database. In addition, reference lists of relevant reviews and websites of clinical trial registry will also be searched. Only randomized controlled trials of furosemide for treatment of LC will be included in this study. Two reviewers will independently select studies, collect data, and determine risk of bias. RevMan 5.3 software will be used to pool the data and to conduct meta-analysis if sufficient studies will be included with acceptable heterogeneity.

RESULTS

This study will investigate the efficacy and safety of furosemide for LC by the assessment of primary and secondary outcomes. The primary outcome includes mortality rate. The secondary outcomes consist of response rate, overall survival, body weight, urinary volume, quality of life, as measured by any relevant scales, and adverse events.

CONCLUSION

The results of this study may provide summarized evidence of furosemide for the treatment of LC.

ETHICS AND DISSEMINATION

No individual patient data will be used in this study, thus no ethics approval is needed. The findings of this study will be published in peer-reviewed journals.

摘要

背景

既往临床研究报道,呋塞米可有效治疗肝硬化(LC)。然而,尚无研究对该问题进行系统探究。本系统评价旨在调查呋塞米治疗LC的疗效和安全性。

方法

本研究将通过检索以下文献来源,检索时间范围从各数据库建库至2019年2月28日,无语言限制:PUBMED、EMBASE、PsycINFO、科学网、Scopus、OpenGrey、考克兰图书馆、护理学与健康照护领域累积索引、补充与替代医学数据库以及中国生物医学文献数据库。此外,还将检索相关综述的参考文献列表以及临床试验注册网站。本研究仅纳入呋塞米治疗LC的随机对照试验。两名评价员将独立选择研究、收集数据并确定偏倚风险。若纳入足够数量且异质性可接受的研究,将使用RevMan 5.3软件汇总数据并进行Meta分析。

结果

本研究将通过评估主要和次要结局来调查呋塞米治疗LC的疗效和安全性。主要结局包括死亡率。次要结局包括缓解率、总生存期、体重、尿量、通过任何相关量表测量的生活质量以及不良事件。

结论

本研究结果可能为呋塞米治疗LC提供总结性证据。

伦理与传播

本研究不使用个体患者数据,因此无需伦理批准。本研究结果将发表在同行评审期刊上。